healthcare
healthcare Articles
Innovative Industrial Properties shares dropped to end the week after the company priced its secondary offering at a discount to its current price level.
Published:
It's a wonder that Ontario-based Aphria survived 2019 at all. Now that it has, what can investors look forward to in 2020?
Published:
Why Credit Suisse believes that this round of quarterly biotech earnings could prove to be a catalyst for 2020.
Published:
New research shows that several members of the coronavirus family are susceptible to inactivation via a system developed by biomedical products company Cerus.
Published:
Applied Genetic Technologies' shares were crushed early on Thursday after the firm reported interim data from its midstage trial in patients with achromatopsia.
Published:
Canada-based pot grower Organigram had the same up-in-smoke year as most of the country's other cannabis producers. The company may get back on track this year.
Published:
Akcea Therapeutics and Ionis Pharmaceuticals each made handy gains on Wednesday after the firms reported midstage results for their cardiovascular disease study.
Published:
China is facing an outbreak of the coronavirus, which may have spread to a few other countries in Asia. As a result, experimental vaccine stocks are skyrocketing.
Published:
For health care investors, 2020 looks like a potentially good year after an especially fruitful JPMorgan Healthcare Conference this past week.
Published:
This past week played host to a huge number of biotech movers. 24/7 Wall St. has picked a few of these standouts to highlight.
Published:
Hexo shares slid on Friday after the Canadian cannabis firm announced that it is conducting a direct offering of $20 million worth of shares.
Published:
Durect shares dropped early on Friday after an FDA committee vote on Posimir, the company’s pain relief treatment.
Published:
Neon Therapeutics shares shot up on Thursday after the firm announced that it will be acquired by BioNTech. Are Neon Therapeutics shareholders getting enough out of the deal?
Published:
Marijuana stocks like Tilray were beaten up badly in 2019. Will 2020 get the industry back in the black?
Published:
Nektar Therapeutics shares were crushed on Wednesday after the FDA did not recommend the company’s pain drug.
Published: